Plain-English translation of NCT07354074 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether asciminib, a new targeted medicine, can safely and effectively treat children with Philadelphia chromosome positive chronic myelogenous leukemia. The trial includes children who are newly diagnosed with this cancer, as well as those who have already received other leukemia medicines. Researchers want to understand how well this medication works and how safe it is for young patients.
Some children with this type of leukemia don't respond well to the current standard medicines, or they develop side effects that are hard to manage. This trial exists to offer a potentially new treatment option for these children, including those whose leukemia has developed resistance to existing drugs.
You likely qualify if…
You likely don't qualify if…
If you are accepted into this trial, you would take the new medication regularly over time while visiting the clinic for check-ups and blood tests. There is no set duration for how long you will receive the treatment — the study will continue to follow and monitor you for safety, growth, and how well the medication is working for up to 5 years after the last enrolled patient starts treatment. Your doctors will watch carefully for any side effects and how your leukemia responds.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States
Australia